Seres Therapeutics: Still Work To Do Before Realizing Its Potential
Seeking Alpha · 05/22 18:49
Acurx Pharmaceuticals Inc: Prospectus [Rule 424(b)(3)]
Press release · 05/18 16:22
Acurx Pharmaceuticals Inc: Prospectus [Rule 424(b)(5)]
Press release · 05/17 16:26
Acurx Pharmaceuticals Inc: Current report
Press release · 05/17 16:20
Acurx Pharmaceuticals down 10% on $4M offering
Seeking Alpha · 05/16 13:10
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
PR Newswire · 05/16 12:45
HC Wainwright & Co. Reiterates Acurx Pharmaceuticals (ACXP) Buy Recommendation
NASDAQ · 05/15 17:24
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $14 Price Target
Benzinga · 05/15 10:46
H.C. Wainwright Keeps Their Buy Rating on Acurx Pharmaceuticals (ACXP)
TipRanks · 05/15 10:25
Acurx Pharmaceuticals (ACXP) Gets a Buy from Maxim Group
TipRanks · 05/13 13:15
BRIEF-Acurx Pharmaceuticals Inc Reports Q1 2023 Results And Provides Business Update
Reuters · 05/12 13:43
Earnings Scheduled For May 12, 2023
Benzinga · 05/12 12:22
Recap: Acurx Pharmaceuticals Q1 Earnings
Benzinga · 05/12 11:15
Acurx Pharmaceuticals Q1 EPS $(0.25) Beats $(0.29) Estimate; Cash At Hand $7.2M
Benzinga · 05/12 11:03
Acurx Pharmaceuticals GAAP EPS of -$0.25
Seeking Alpha · 05/12 11:02
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update
PR Newswire · 05/12 11:01
Pre-Market Earnings Report for May 12, 2023 : CPG, SPB, HUMA, SHCO, AIRS, ADAP, AUGX, CAAS, DCTH, ACXP, RGF, LGVN
NASDAQ · 05/11 20:00
A Preview Of Acurx Pharmaceuticals's Earnings
Benzinga · 05/11 15:00
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update
PR Newswire · 05/05 21:01
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference
PR Newswire · 04/19 11:01
Webull provides a variety of real-time ACXP stock news. You can receive the latest news about Acurx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACXP
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). The Company develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. The Company’s research and development pipeline includes clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile; Enterococcus, including vancomycin-resistant strain; Staphylococcus, including methicillin-resistant strains, and Streptococcus, including antibiotic resistant strains).